X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
NOVARTIS INDIA LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

NOVARTIS INDIA LIMITED   (NVRT)


Here is the latest financial fact sheet of Novartis. For more details, see the Novartis quarterly results and Novartis share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
NOVARTIS - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 709.8       No. of shares m 335.46
    Mkt Cap Rs m 238,110       % ch % -0.2
    Vol '000 2.4       % ch week % -1.9
    P/E X 314.0       % ch 1-mth % 6.7
    P/CF X 118.7       % ch 12-mth % -7.2
    EPS (TTM) Rs 2.3       52 week H/L Rs 855.0/630.0
(As on Apr 26, 2017 11:27:00 AM) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
12
Mar-13
12
Mar-14
12
Mar-15
12
Mar-16
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs944934605760982 
Low Rs617565361438556 
Sales per share (Unadj.) Rs264.2282.7269.8273.3252.9 
Earnings per share (Unadj.) Rs47.637.530.824.862.1 
Diluted earnings per shareRs4.53.62.92.45.9 
Cash flow per share (Unadj.) Rs48.438.632.026.063.3 
Dividends per share (Unadj.) Rs10.0010.0010.0010.0010.00 
Adj. dividends per shareRs0.950.950.950.950.95 
Dividend yield (eoy) %1.31.32.11.71.3 
Book value per share (Unadj.) Rs255.9281.7300.8313.5363.6 
Adj. book value per shareRs24.426.828.729.934.6 
Shares outstanding (eoy) m31.9631.9631.9631.9631.96 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x3.02.71.82.23.0 
Avg P/E ratio x16.420.015.724.212.4 
P/CF ratio (eoy) x16.119.415.123.012.2 
Price / Book Value ratio x3.02.71.61.92.1 
Dividend payout %21.026.732.440.416.1 
Avg Mkt Cap Rs m24,94523,95415,43319,14724,580 
No. of employees `0001.41.41.31.20.8 
Total wages/salary Rs m1,3771,6231,7422,0001,801 
Avg. sales/employee Rs Th6,212.66,555.66,663.37,236.010,748.9 
Avg. wages/employee Rs Th1,013.11,177.81,346.11,657.22,395.2 
Avg. net profit/employee Rs Th1,118.6868.9761.4655.42,641.1 
  INCOME DATA
Net Sales Rs m8,4439,0348,6228,7348,083 
Other income Rs m8408329511,076829 
Total revenues Rs m9,2839,8669,5749,8108,913 
Gross profit Rs m1,439900-13-39234 
Depreciation Rs m2736374037 
Interest Rs m52322 
Profit before tax Rs m2,2471,6948999961,025 
Minority Interest Rs m00000 
Prior Period Items Rs m38439616517 
Extraordinary Inc (Exp) Rs m000-631,696 
Tax Rs m730581310306752 
Profit after tax Rs m1,5201,1979857911,986 
Gross profit margin %17.010.0-0.2-0.42.9 
Effective tax rate %32.534.334.530.773.4 
Net profit margin %18.013.311.49.124.6 
  BALANCE SHEET DATA
Current assets Rs m9,32710,33510,61010,63412,678 
Current liabilities Rs m1,9312,1222,1222,1072,433 
Net working cap to sales %87.690.998.597.6126.7 
Current ratio x4.84.95.05.05.2 
Inventory Days Days3445444233 
Debtors Days Days3033333522 
Net fixed assets Rs m102102798569 
Share capital Rs m160160160160160 
"Free" reserves Rs m8,0178,8419,4529,85911,460 
Net worth Rs m8,1799,0029,61410,02011,621 
Long term debt Rs m10000 
Total assets Rs m10,16411,41212,02112,46114,400 
Interest coverage x417.1771.1334.0475.1570.5 
Debt to equity ratio x00000 
Sales to assets ratio x0.80.80.70.70.6 
Return on assets %15.010.58.26.413.8 
Return on equity %18.613.310.27.917.1 
Return on capital %27.619.813.511.023.6 
Exports to sales %0.50.60.90.90.7 
Imports to sales %17.719.421.814.218.6 
Exports (fob) Rs m4550798060 
Imports (cif) Rs m1,4961,7491,8771,2441,503 
Fx inflow Rs m86125144149186 
Fx outflow Rs m1,8672,1372,3351,6451,821 
Net fx Rs m-1,781-2,012-2,191-1,497-1,635 
  CASH FLOW
From Operations Rs m 747 74 -46 -596 2,531 
From Investments Rs m -427 -161 222 7,189 -8,270 
From Financial Activity Rs m -375 -373 -378 -377 -386 
Net Cashflow Rs m -55 -460 -202 6,217 -6,125 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for novartis india limited

 Share Holding
Indian Promoters : 0.0%
Foreign collaborators : 75.0%
Indian inst/Mut Fund : 2.0%
FIIs : 1.6%
ADR/GDR : 0.0%
Free float : 21.5%
Shareholders : 41,647
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: Sandoz House, Shivsagar Estate, Dr. Annie Besant Road, Mumbai-18
    E-MAIL: girish.tekchandani@novartis.com     WEB: www.novartis.in
    TELEPHONE: (022) 2495 8400     FAX: (022) 2495 0221
    SECTOR: PHARMACEUTICALS     GROUP: M N C
    TR AGENT: Sharepro Serv., 13 AB, Samhita Warehousing, Andheri (E), Mumbai-72
    AUDITOR: Lovelock and Lewes
CHM: C. Snook COMP SEC: Girish Tekchandani YEAR OF INC: 1947 BSE CODE: 500672 FV (Rs): 5 DIV YIELD (%): 0.1

More pharmaceuticals Company Fact Sheets:   IPCA LABSGLENMARK PHARMACADILA HEALTHCAREORCHID PHARMA LTDGSK PHARMA


Today's Market

Sensex Crosses 30,000-Mark; Wipro Gains 3.3% on Q4 Results(09:30 am)

Asian equity markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.34%, while the Hang Seng is up 0.61%. The Nikkei 225 is trading higher by 0.79%.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

Aur Bhi Dukh Hain Zamane Main Stock Market Ke Siva...(Vivek Kaul's Diary)

Apr 13, 2017

The link between the Indian economy and the stock market is weak, and the stock market is not a reflection of the Indian economy.

The Real Reason Indiabulls Real Estate Jumped 42%(Daily Profit Hunter)

Apr 19, 2017

An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.

7 Benefits Of Creating A CAN(Outside View)

Apr 13, 2017

The MFU platform offers ease, convenience, and speed of transacting in various mutual fund schemes.

More

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NOVARTIS

NOVARTIS - DR. DATSONS LABS COMPARISON

Compare Company With Charts

COMPARE NOVARTIS WITH

MARKET STATS